Chapter title |
TLR-9 Agonist Immunostimulatory Sequence Adjuvants Linked to Cancer Antigens.
|
---|---|
Chapter number | 27 |
Book title |
Cancer Vaccines
|
Published in |
Methods in molecular biology, March 2014
|
DOI | 10.1007/978-1-4939-0345-0_27 |
Pubmed ID | |
Book ISBNs |
978-1-4939-0344-3, 978-1-4939-0345-0
|
Authors |
Shirota H, Klinman DM, Hidekazu Shirota, Dennis M. Klinman, Shirota, Hidekazu, Klinman, Dennis M. |
Abstract |
The primary goal of cancer vaccines is to elicit tumor-specific cytotoxic T lymphocytes (CTL) capable of eradicating established tumors and preventing/eradicating their metastatic spread. CpG oligonucleotides (CpG ODN) activate and support the maturation of immune cells, including plasmacytoid dendritic cells and B lymphocytes, that express Toll-like receptor 9 (TLR9) and are capable of presenting tumor antigens to T cells. Thus, CpG ODN are effective vaccine adjuvants. The adjuvant activity of CpG ODN is improved by maintaining them in close physical and temporal proximity to the co-administered vaccine antigen. This work describes a method of chemically conjugating CpG ODN to antigens and/or cancer cells that improve the resulting CTL response. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 5 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Doctoral Student | 2 | 40% |
Student > Postgraduate | 1 | 20% |
Student > Master | 1 | 20% |
Unknown | 1 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Veterinary Science and Veterinary Medicine | 1 | 20% |
Biochemistry, Genetics and Molecular Biology | 1 | 20% |
Medicine and Dentistry | 1 | 20% |
Unknown | 2 | 40% |